Abstract: Virology Journal
https://doi.org/10.1186/s12985-025-03057-2
Article in Press
Viral kinetics in adults with Covid-19 treated
with nirmatrelvir-ritonavir or molnupiravir: a
population-based, observational cohort study
Received: 11 November 2025
Accepted: 21 December 2025
Cite this article as: Prager M., Ensle D.,
Eser H. et al. Viral kinetics in adults with
Covid-19 treated with nirmatrelvirritonavir or molnupiravir: a populationbased, observational cohort study.
Virol J (2025). https://doi.org/10.1186/
s12985-025-03057-2
A
Marlene Prager, Dominik Ensle, Hubert Eser, Florentin Glötzl, Benjamin Riedl,
Marton Szell, Arschang Valipour, Alexander Zoufaly, Christoph Wenisch, Doris Haider,
Heinz Burgmann, Florian Thalhammer, Florian Götzinger, Bernd Jilma, Ursula
Karnthaler, Markus Zeitlinger & Anselm Jorda
E
R
P
S
S
We are providing an unedited version of this manuscript to give early access to its
findings. Before final publication, the manuscript will undergo further editing. Please
note there may be errors present which affect the content, and all legal disclaimers
apply.
IN
If this paper is publishing under a Transparent Peer Review model then Peer
Review reports will publish with the final article.
I
T
R
E
L
C
© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit
to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do
not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
ACCEPTED
ARTICLE IN
MANUSCRIPT
PRESS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
Viral kinetics in adults with Covid-19 treated with
nirmatrelvir-ritonavir
or
molnupiravir:
a
population-based, observational cohort study
Running Title: Viral kinetics after nirmatrelvir-ritonavir and molnupiravir
Marlene Prager1, Dominik Ensle2, Hubert Eser3, Florentin Glötzl4, Benjamin Riedl5,
Marton Szell6, Arschang Valipour7, Alexander Zoufaly8, Christoph Wenisch8, Doris
Haider9, Heinz Burgmann10, Florian Thalhammer11, Florian Götzinger12, Bernd
Jilma1, Ursula Karnthaler2, Markus Zeitlinger1*, Anselm Jorda1
1Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
²Municipal Department for Public Health Services of the City of Vienna, Vienna, Austria
3Municipal Department for Information Technology of the City of Vienna, Vienna, Austria
4Institute
for Ecological Economics, Department for Socioeconomics, Vienna University of Economics and Business,
Vienna, Austria
5Department of Research, Vienna Healthcare Group, Vienna, Austria
6Department of Internal Medicine 2, Emergency Department, Klinik Donaustadt, Vienna,..
DOI record:
{
"DOI": "10.1186/s12985-025-03057-2",
"ISSN": [
"1743-422X"
],
"URL": "http://dx.doi.org/10.1186/s12985-025-03057-2",
"alternative-id": [
"3057"
],
"assertion": [
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Received",
"name": "received",
"order": 1,
"value": "11 November 2025"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Accepted",
"name": "accepted",
"order": 2,
"value": "21 December 2025"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "First Online",
"name": "first_online",
"order": 3,
"value": "10 January 2026"
},
{
"group": {
"label": "Declarations",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 1
},
{
"group": {
"label": "Ethics approval and consent to participate",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 2,
"value": "Ethical approval for this study was given from the Ethics Committee of the City of Vienna (ID: EK23-146-VK)."
},
{
"group": {
"label": "Consent for publication",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 3,
"value": "Not applicable."
},
{
"group": {
"label": "Competing interests",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 4,
"value": "The authors declare no competing interests."
}
],
"author": [
{
"affiliation": [],
"family": "Prager",
"given": "Marlene",
"sequence": "first"
},
{
"affiliation": [],
"family": "Ensle",
"given": "Dominik",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Eser",
"given": "Hubert",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Glötzl",
"given": "Florentin",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Riedl",
"given": "Benjamin",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Szell",
"given": "Marton",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Valipour",
"given": "Arschang",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zoufaly",
"given": "Alexander",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wenisch",
"given": "Christoph",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Haider",
"given": "Doris",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Burgmann",
"given": "Heinz",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Thalhammer",
"given": "Florian",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Götzinger",
"given": "Florian",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Jilma",
"given": "Bernd",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Karnthaler",
"given": "Ursula",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zeitlinger",
"given": "Markus",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Jorda",
"given": "Anselm",
"sequence": "additional"
}
],
"container-title": "Virology Journal",
"container-title-short": "Virol J",
"content-domain": {
"crossmark-restriction": false,
"domain": [
"link.springer.com"
]
},
"created": {
"date-parts": [
[
2026,
1,
10
]
],
"date-time": "2026-01-10T00:53:00Z",
"timestamp": 1768006380000
},
"deposited": {
"date-parts": [
[
2026,
1,
10
]
],
"date-time": "2026-01-10T00:53:04Z",
"timestamp": 1768006384000
},
"indexed": {
"date-parts": [
[
2026,
1,
10
]
],
"date-time": "2026-01-10T06:04:13Z",
"timestamp": 1768025053413,
"version": "3.49.0"
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2026,
1,
10
]
]
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by-nc-nd/4.0",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2026,
1,
10
]
],
"date-time": "2026-01-10T00:00:00Z",
"timestamp": 1768003200000
}
},
{
"URL": "https://creativecommons.org/licenses/by-nc-nd/4.0",
"content-version": "am",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2026,
1,
10
]
],
"date-time": "2026-01-10T00:00:00Z",
"timestamp": 1768003200000
}
}
],
"link": [
{
"URL": "https://link.springer.com/article/10.1186/s12985-025-03057-2",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "297",
"original-title": [],
"prefix": "10.1186",
"published": {
"date-parts": [
[
2026,
1,
10
]
]
},
"published-online": {
"date-parts": [
[
2026,
1,
10
]
]
},
"publisher": "Springer Science and Business Media LLC",
"reference": [
{
"key": "3057_CR1",
"unstructured": "COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. [Internet]. 2024 Feb. Available from: https://www.covid19treatmentguidelines.nih.gov/"
},
{
"DOI": "10.15585/mmwr.mm7251a2",
"doi-asserted-by": "crossref",
"key": "3057_CR2",
"unstructured": "Harrington PR, Cong J, Troy SB, Rawson JMO, Julian;, O’rear J et al. Morbidity and Mortality Weekly Report Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials-United States and International Sites, 2021–2022 [Internet]. Vol. 22. 2023. Available from: www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217188Orig1s000ltr.pdf"
},
{
"DOI": "10.1093/cid/ciac481",
"author": "N Ranganath",
"doi-asserted-by": "crossref",
"first-page": "E537",
"issue": "3",
"journal-title": "Clin Infect Dis",
"key": "3057_CR3",
"unstructured": "Ranganath N, O’Horo JC, Challener DW, Tulledge-Scheitel SM, Pike ML, O’Brien M, et al. Rebound phenomenon after Nirmatrelvir/Ritonavir treatment of coronavirus disease 2019 (COVID-19) in High-Risk persons. Clin Infect Dis. 2023;76(3):E537–9.",
"volume": "76",
"year": "2023"
},
{
"DOI": "10.1001/jamanetworkopen.2022.45086",
"doi-asserted-by": "crossref",
"key": "3057_CR4",
"unstructured": "Wong GLH, Yip TCF, Lai MSM, Wong VWS, Hui DSC, Lui GCY. Incidence of viral rebound after treatment with Nirmatrelvir-Ritonavir and molnupiravir. JAMA Netw Open. 2022;5(12):e2245086."
},
{
"DOI": "10.1056/NEJMc2206449",
"author": "ME Charness",
"doi-asserted-by": "crossref",
"first-page": "1045",
"issue": "11",
"journal-title": "N Engl J Med",
"key": "3057_CR5",
"unstructured": "Charness ME, Gupta K, Stack G, Strymish J, Adams E, Lindy DC, et al. Rebound of SARS-CoV-2 infection after Nirmatrelvir–Ritonavir treatment. N Engl J Med. 2022;387(11):1045–7.",
"volume": "387",
"year": "2022"
},
{
"DOI": "10.1001/jamanetworkopen.2024.1765",
"author": "Z Yang",
"doi-asserted-by": "crossref",
"first-page": "E241765",
"issue": "3",
"journal-title": "JAMA Netw Open",
"key": "3057_CR6",
"unstructured": "Yang Z, Xu Y, Zheng R, Ye L, Lv G, Cao Z, et al. COVID-19 rebound after VV116 vs Nirmatrelvir-Ritonavir treatment: a randomized clinical trial. JAMA Netw Open. 2024;7(3):E241765.",
"volume": "7",
"year": "2024"
},
{
"DOI": "10.1186/s12879-023-08835-3",
"doi-asserted-by": "crossref",
"key": "3057_CR7",
"unstructured": "Schilling WHK, Jittamala P, Watson JA, Boyd S, et al; PLATCOV Collaborative Group. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis. 2024;24(1):36–45."
},
{
"DOI": "10.1038/s41467-024-49458-9",
"doi-asserted-by": "crossref",
"key": "3057_CR8",
"unstructured": "Esmaeili S, Owens K, Wagoner J, Polyak SJ, White JM, Schiffer JT. A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy. Nat Commun. 2024;15(1):5478."
},
{
"DOI": "10.1128/jvi.01623-24",
"doi-asserted-by": "crossref",
"key": "3057_CR9",
"unstructured": "Phan T, Ribeiro RM, Edelstein GE, Boucau J, Uddin R, Marino C, et al. Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance. J Virol. 2025;99(3):e0162324."
},
{
"DOI": "10.1016/j.cmi.2024.10.026",
"author": "A Jorda",
"doi-asserted-by": "crossref",
"first-page": "451",
"issue": "3",
"journal-title": "Clin Microbiol Infect",
"key": "3057_CR10",
"unstructured": "Jorda A, Ensle D, Eser H, Glötzl F, Riedl B, Szell M, et al. Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized adults with COVID-19: a population-based, retrospective cohort study. Clin Microbiol Infect. 2025;31(3):451–8.",
"volume": "31",
"year": "2025"
},
{
"DOI": "10.1093/cid/ciaa619",
"author": "MR Tom",
"doi-asserted-by": "crossref",
"first-page": "2252",
"journal-title": "Clin Infect Dis",
"key": "3057_CR11",
"unstructured": "Tom MR, Mina MJ, Oxford University Press. To interpret the SARS-CoV-2 test, consider the cycle threshold value. Clin Infect Dis. 2020;71:2252–4.",
"volume": "71",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2118542",
"author": "J Hammond",
"doi-asserted-by": "crossref",
"first-page": "1397",
"issue": "15",
"journal-title": "N Engl J Med",
"key": "3057_CR12",
"unstructured": "Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for High-Risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–408.",
"volume": "386",
"year": "2022"
}
],
"reference-count": 12,
"references-count": 12,
"relation": {},
"resource": {
"primary": {
"URL": "https://link.springer.com/10.1186/s12985-025-03057-2"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Viral kinetics in adults with Covid-19 treated with nirmatrelvir-ritonavir or molnupiravir: a population-based, observational cohort study",
"type": "journal-article",
"update-policy": "https://doi.org/10.1007/springer_crossmark_policy"
}
